Aerie Pharmaceuticals Long Term Debt

Aerie Pharmaceuticals (AERI) currently reports a long-term debt of $310M as of September 2022. That compares with $230M in the prior-year period — up 37.0% year over year. Use the charts on this page to explore Aerie Pharmaceuticals's long-term debt history and peer comparisons.

Aerie Pharmaceuticals's long-term debt increased from $230M to $310M — a 37.0% year-over-year increase (period ending September 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Aerie Pharmaceuticals reported $310M in long-term debt as of September 2022. That compares with $230M in the prior-year period — up 37.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $310M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Aerie Pharmaceuticals, and consider following AERI for alerts when major investors trade the stock.

Aerie Pharmaceuticals is classified in the Healthcare sector. On long-term debt, it currently shows $310M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AERI with unrelated industries.